Asahi Kasei Pharma Obtains All Intellectual Property Rights To Roche's Flivas
This article was originally published in PharmAsia News
Asahi Kasei Pharma signed a licensing agreement with Roche Diagnostics and obtained all intellectual property rights related to Flivas (naftopidil), a drug indicated to treat urination difficulty associated with benign prostate hyperplasia. The company obtained naftopidil's Japanese domestic marketing right in 1999 and current annual sales are ¥11.5 billion. With a strategic focus on urology drug business, Asahi Kasei Pharma also aims to expand to overseas markets. (Click here for more - Japanese language) "Asahi Kasei Pharma Obtains All Intellectual Property Rights To BPH Drug From German Company" - Nikkei Sangyo News (11/18/08)
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.